<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7102646/results/search/test_trace/results.xml">
  <result pre="patients and reduce the danger of the mysterious new viral" exact="infection" post="COVID-19. The drugs mentioned above can tightly bind to"/>
  <result pre="WHO distributed interim guidance for laboratories that carry out the" exact="testing" post="for the newly-emerged outbreak, as well as infection prevention"/>
  <result pre="out the testing for the newly-emerged outbreak, as well as" exact="infection" post="prevention and control guidance [5,6]. The COVID-19 pneumonia is"/>
  <result pre="of 95.9%). 3.2 Drugs binding to SARS-CoV-2 RdRp Prior to" exact="testing" post="the ligands against SARS-CoV-2 RdRp, the structures of the"/>
  <result pre="on the market or in clinical trials, to stop the" exact="infection" post="immediately. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir showed promising"/>
 </snippets>
</snippetsTree>
